
Elige tu etiqueta
se ve directamente en el vialReta + Tesamorelin Blend
GLP-1
- Envío desde Alemania
Pedido
- DHL con seguimiento
- Embalaje discreto
De un vistazo
Reta + Tesamorelin Blend en cifras
Las cifras clave de nuestra enciclopedia.
Entrada completa de la enciclopedia- Type
- Injectable blendtriple agonist + GHRH analog
- Sizes
- 20 mg1 size in the shop
What studies show
All 4 sources in the lexiconRetatrutide phase 2 trial (obesity), 48 weeks, NEJM 2023 (opens in a new tab)
New England Journal of Medicine (PubMed PMID 37366315)Retatrutide systematic review + meta-analysis (878 patients), 2025 (opens in a new tab)
Proc (Bayl Univ Med Cent) (PubMed PMID 40291085)Tesamorelin phase 3 trial (visceral fat, HIV), 12 months (opens in a new tab)
J Acquir Immune Defic Syndr (PubMed PMID 20101189)
Reseñas
Lo que dicen los clientes
Solo pedidos reales que incluían Reta + Tesamorelin Blend.
Todas las reseñasTodavía no hay ningún análisis de laboratorio de Reta + Tesamorelin Blend. Vota por élHazlo analizar tú mismo, pagamos la mitadTodos los análisis de laboratorio
Conocimiento
Todo sobre Reta + Tesamorelin Blend
Información detallada próximamente.
Dosificación
Cargando información de dosificación …
Conviene tenerlo
Lo que necesitas con ello
El agua bacteriostática se añade automáticamente a tu carrito. Jeringas y toallitas con un clic.
Jeringas de insulina
10 uds. · 5.50 €
Toallitas con alcohol
50 uds. · 10 €
¿Cuánta agua?
Unidades en la jeringa para tu tamaño de vial.
Abrir calculadora →Is the Reta + Tesamorelin Blend approved or studied?
No. As of 26 October 2026 the registry ClinicalTrials.gov lists no trial with Retatrutide and tesamorelin together. Tesamorelin alone has been approved in the USA since 2010, Retatrutide is in phase 3 and not approved.
What is the catch with the fixed mix?
The two substances were studied on very different schedules: Retatrutide once a week, tesamorelin daily. In a 1:1 vial the ranges from both trial programmes cannot be matched at the same time. The entry therefore goes by the Retatrutide share.
What do the Retatrutide trials show?
In phase 2 body weight fell by 24.2 percent after 48 weeks at the highest study dose, by 2.1 percent on placebo. In phase 3 (TRIUMPH-1) it was 25.0 versus 3.9 percent after 80 weeks. A meta-analysis with 878 participants confirmed clear effects on weight and metabolic values.
What do the tesamorelin trials show?
In 806 patients with HIV and excess belly fat, visceral fat fell by 15.4 percent more than on placebo in 26 weeks, subcutaneous fat stayed nearly the same. IGF-1 rose, blood sugar stayed stable. Those who continued kept the effect to week 52.
Which side effects were seen with the components?
Retatrutide: mainly nausea, diarrhoea and other gastrointestinal effects, depending on the dose, plus a slight rise in heart rate. Tesamorelin: injection site reactions, joint and muscle pain, fluid retention and tingling. There is no safety profile for the blend.
Which trials are still running?
Nine phase 3 trials of Retatrutide are running, the largest on heart and kidney events until 2029. The phase 3 trials of tesamorelin were completed years ago. No trial of the blend is listed in the registry.
Relacionados
Productos relacionados
Tirzepatide
Péptidos · GLP-1 y pérdida de grasa GLP-1 y pérdida de grasa
10 tamaños
Analizado en laboratorio
= desde 10 €/vial
Retatrutide
Péptidos · GLP-1 y pérdida de grasa GLP-1 y pérdida de grasa
11 tamaños
Analizado en laboratorio
= desde 16 €/vial
Semaglutide
Péptidos · GLP-1 y pérdida de grasa GLP-1 y pérdida de grasa
6 tamaños
Analizado en laboratorio
= desde 10 €/vial
Mazdutide
Péptidos · GLP-1 y pérdida de grasa GLP-1 y pérdida de grasa
2 tamaños
= desde 32 €/vial
Reta + Tesamorelin Blend